Timing of Temozolomide for Glioblastoma Treatment
Official title: A Randomized, Multicentre Pilot Trial Evaluating the Feasibility and Efficacy of Dose Timing (Morning vs Evening) of Temozolomide in the Treatment of Glioblastoma
Run by Ottawa Hospital Research Institute · NCT06850766 · Data updated 2026-11-12
This study is testing whether taking the cancer drug temozolomide in the morning or evening helps people with glioblastoma feel better and have fewer side effects.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Ottawa Hospital Research Institute Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 2 sites (London, Ontario and 1 other locations) |
| Status | Recruiting |
| Started | May 8, 2025 |
| Main results expected | May 2027 |
| Study ends | November 2031 |
| Registry record updated | July 16, 2026 |
| Trial ID | NCT06850766 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with newly diagnosed IDH-wildtype glioblastoma who have completed brain tumor resection and postoperative radiation therapy.
✕Probably not a fit
Patients with metastatic or incurable cancers other than IDH-wildtype glioblastoma may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the feasibility and efficacy of administering temozolomide (TMZ) at different times of the day (morning vs evening) for patients with IDH-wildtype glioblastoma. Participants will be randomly assigned to one of the two groups and will take their medication according to their assigned schedule while recording the timing of their doses. The goal is to determine if the timing of TMZ administration can enhance its effectiveness and reduce side effects, based on the body's circadian rhythms. This pilot trial aims to inform future larger studies on the optimal timing for TMZ treatment.
Why it matters
Potential benefit: If successful, this approach could improve treatment outcomes for glioblastoma patients by optimizing the timing of chemotherapy.
How similar studies have gone: Previous studies have shown success with chronotherapy in other cancer types, suggesting potential for this approach in glioblastoma treatment.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years of age or older * Newly diagnosed IDH-wildtype glioblastoma * Completed maximal safe brain tumor resection * Completed post-operative brain RT * Plan to proceed with up to 6 cycles of adjuvant TMZ within 8 weeks of completing post-operative RT * Able and willing to provide oral informed consent Exclusion Criteria: * Unable or unwilling to complete study questionnaires * Metastatic or incurable cancer other than IDH-wild type glioblastoma
Where it's running
-
London Health Sciences Centre
London, Ontario, Canada Recruiting -
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada Recruiting
Study contacts
- Principal investigator: Terry Ng, MD — The Ottawa Hospital Cancer Centre
- Study coordinator: Lisa Vandermeer, MSc
- Email: lvandermeer@ohri.ca
- Phone: 613-737-7700
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Brain connectome project in adults with brain glioma undergoing surgery
This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.
-
Metabolomics and Transcriptomics of Gliomas
Researchers are testing whether metabolic and gene-expression profiles can reveal new glioma subgroups and improve models to study and develop treatments for IDH wildtype glioblastoma and IDH-mutant lower-grade gliomas.
-
Targeted radioligand therapy for recurrent glioblastoma with Lu-177 XT771
This early-phase study tests whether a radiolabeled medicine (Lu-177 XT771) delivered directly into the tumor cavity is safe and tolerable for adults with recurrent glioblastoma.
-
Personalized Targeted Glioblastoma Therapies Guided by Ex Vivo Drug Screening
This trial tests whether using a patient’s own tumor cells to screen drugs can guide a personalized treatment plan for people with newly diagnosed glioblastoma undergoing short-course radiotherapy.
-
LITT for ultra-early GBM recurrence within 1 week of pre-radiation planning
This study tests whether a minimally invasive laser treatment can destroy an early GBM recurrence without delaying planned radiotherapy and chemotherapy.
-
Combined intracranial and intravenous NK cell therapy for malignant brain tumors
This trial will test whether giving adults with recurrent malignant brain tumors their own expanded and activated natural killer (NK) cells into the tumor site and into the bloodstream is safe and feasible.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.